Case Studies in Better Pre-Clinical Prediction Using Hurel Cell-based Liver Models (October 14, 2015)
Hurel Corporation is pleased to sponsor an ISSX industry-sponsored session: “Case Studies in Better Pre-Clinical Prediction Using Hurel’s Robust, Primary Hepatocyte Co-Cultures”, from 7:30-8:45AM on Tuesday morning, October 20. The session will be moderated by ISSX 2015 Scientific Award winner and Hurel Co-Founder Leslie Z. Benet,Ph.D. and will include three panelist presentations. Hurel Chief Scientific Officer Eric Novik, Ph.D., will offer a technical characterization overview of the Hurel cell-based hepatic models. J. Matthew Hutzler, Ph.D., Director, Q2 Solutions Bioanalytical and ADME Labs, will discuss the clearance and metabolite generation results that Q2 recently produced using the Hurel human and rat cell-based liver models, which form the basis of the poster Q2 is presenting at ISSX. And Mark Warren, Ph.D., Senior Principal Investigator, Optivia Biotechnology, will explain the new method Optivia has developed, using the Hurel models, to produce more human-relevant prediction of cholestatic liabilities in an in vitro, cell-based platform. Dr. Benet will lead the three discussants in a panel discussion as well as invite questions from the scientific audience.

Continental breakfast refreshments will be served.

ISS #3
Tuesday, October 20
Rm. Floridian A-I

multi-readout, repeat-dose
DILI screening
DILI screening

Hurel microlivers afford better prediction than 3D

Toxicology Research
Long-enduring infectious liver disease platform
Toxicity Ratios*
A new marker for hepatotoxic chronicity

*patent pending
a new, patent-pending
efflux transport
assay method
Superior intrinsic clearance
and biotransformation of
low-turnover drugs